I
n a long-awaited decision, the National Institutes of Health rejected a petition urging the agency to use a controversial provision of federal law to widen access to a cancer drug by forcing the manufacturers to license their patents.
{iframe}https://www.statnews.com/pharmalot/2023/03/22/nih-cancer-patents-bayh-dole-xtandi/?utm_campaign=pharmalittle&utm_medium=email&_hsmi=251268307&utm_content=251268307&utm_source=hs_email{/iframe}